Endocrinological Management and Treatment of Adult Gender Dysphoric. Patients
|
|
- Letitia Morgan
- 5 years ago
- Views:
Transcription
1 Endocrinological Management and Treatment of Adult Gender Dysphoric Leighton Seal PhD FRCP Consultant Endocrinologist Gender Identity Clinic Tavistock And Portman NHS Trust Patients
2 Outline Biological Model of gender development Terminology Treatment of Transgendered women Treatment of Transgendered Men Long Term outcome
3
4
5
6
7
8
9 Sexually Dimorphic Nuclei Hypothalamic Sexually dimorphic nucleus of the hypothalamus Bed nucleus of the stria terminalis Suprachisamatic nucleus Corpus callosum Spinal motor nucleus of the bulbocavernosus Dentate gyrus of the hippocampus Cortical thickness Amygdala
10 Evidence from animal Concentrate both oestrogens and androgens Highest levels of androgen receptor expression High levels of oestrogen receptor expression High Aromatase activity models Androgen and oestrogen administration at critical period can alter neuronal nuclear size and neuronal numbers
11 Testosterone ( nmol/l) 30 Plasma Testosterone Levels term weeks weeks years Foetal Age Postnatal Age
12 Sexually Dimorphic Nuclei In Humans Corpus callosum Sexually dimorphic nucleus of the preoptic area
13
14 Sexually Dimorphic Nuclei of the Hypothalamus In Humans Allen did not find a difference in overall POA and found several neuronal clusters Interstital Nucluei of the Hypothalamus (1-4) INH 2 2x larger in males INH 3.2 larger in women of reproductive years that non reproductive INH 3 2.8x larger in males
15 male female Zhou 1995 Nature
16 Hormonally Influenced Sex Specific Behaviours in Humans Sexual Orientation Core Sexual Identity Rough Play Aggression Visio spacial ability Verbal skills Hand preference
17 Complete Androgen Insensitivity
18 Congenital Adrenal Hyperplasia
19 heterosexual male heterosexual female homosexual male transwoman Zhou 1995 Nature
20 Role of Endocrinologist in the Management of Gender Diagnosis of associated endocrine abnormalities Dysphoria Hormonal treatment of transgender patients
21 Associated Conditions Intersex Congenital adrenal hyperplasia Androgen insensitivity Gonadal dysgenesis 5α reductase deficiency Aromatase deficiency Chromosomal abnormality Kleinfelter s syndrome Turner s Syndrome Exogenous Hormone exposure
22 Incidence of Transsexualism 1:30,000 natal males. 1:100,000 natal females seek SRS. (APA, 2000) 1:7440 for natal males 1:31,153 for natal females. (Wilson, Sharp and Carr, 1999) A non-conservative estimate is that 8-10% of the United States population has some degree of GD. (Ettner,1999) 5% of population seeking trans related services (NHS Calderdale, 2009)
23 Subjects(%) Birth Gender (%) Male Female
24 Age (years) Age at Baseline Transwoman Transman
25 Terminology Gender Non Conformity Gender Dysphoria Non Binary Gender Identity
26
27 Gender Dysphoria DSM-V a marked difference between the individual s expressed/experienced gender and the gender others would assign him or her, and it must continue for at least six months. In children, the desire to be of the other gender must be present and verbalized. This condition causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.
28
29
30 ICD-10 Transsexualism The desire to live and be accepted as a member of the opposite sex usually accompanied by the wish to make his or her body as congruent as possible with the preferred sex through surgery and hormone treatment The transgender identity has been present for a minimum of 2 years The disorder is not a symptom of another mental disorder or chromosomal disorder
31 ICD 11 Will remove Gender Identity disorders from mental health section Gender Incongruence A marked incongruence between one s experienced/expressed gender and assigned gender, of at least 6 months duration, as manifested by 2* or more of the following indicators: 1. a marked incongruence between one s experienced/expressed gender and primary and/or secondary sex characteristics (or, in young adolescents, the anticipated secondary sex characteristics) 2. a strong desire to be rid of one s primary and/or secondary sex characteristics because of a marked incongruence with one s experienced/expressed gender (or, in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics) 3. a strong desire for the primary and/or secondary sex characteristics of the other gender 4. a strong desire to be of the other gender (or some alternative gender different from one s assigned gender) 5. a strong desire to be treated as the other gender (or some alternative gender different from one s assigned gender) 6. a strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one s assigned gender)
32 ICD 10 Diagnosis Adult Specialist Mental health professional with appropriate qualification in that field Specialised training in the diagnosis of DSM/IDC-10 Sexual Disorders Training in psychotherapy CPD in gender disorders
33 Tridadic Therapy The principal of treatment is Tridadic Therapy Social Gender Role Change Hormonal Therapy of the Desired Gender Genital Reconstrucitve Surgery GRS Hormones SGRC
34 Screening tests LH FSH Testosterone Oestradiol SHBG Prolactin Dihydrotestosterone PSA (Karyotype) LFT FBC Lipids Glucose Weight BMI BP
35 Vitamin D levels in those taking and not taking hormones prior to clinic attendance
36 Aim of therapy To Suppress genetic sex hormone production Induce sexual development of desired gender Prevent long term complications of hypogonadism
37 Hormone Regimens Used Moore JCEM
38 Transwomen
39 Oestrogen Effects in Transwomen EFFECT ONSET MAXIMUM Redistribution of body fat months Decrease in muscle mass and strength Softening of skin/decreased oiliness Decreased libido Decreased spontaneous erections Male sexual dysfunction Breast growth Decreased testicular volume Decreased sperm production Decreased terminal hair growth Scalp hair Voice changes months 3 6 months 1 3 months 1 3 months Variable 3 6 months 3 6 months Unknown 6 12 months No regrowth None 2 3 years 1 2 years Unknown 3 6 months 3 6 months Variable 2 3 years 2 3 years > 3 years > 3 years Hembree JCEM 2009, 94(9):
40 Time Course of Breast Development in Transwomen Mayer III 1986 Arch of Sex Behav 15 (2)
41 Hormone Replacement Maximum effect takes up to 2 years Transwomen 5 years Transmen Increasing doses does not lead to increasing effect Response is individual Genetic make up limits the tissue response
42 Need for Augmentation by Selfmedication Status 12 * 10 Subjects (%) Augmentation No Augmentation Seal JECM :
43 Need for Augmentation by Oestrogen Type Subjects (%) 50% 45% 40% 35% 30% 25% 20% 15% 10% 5% Augmentation No Augmentation 0% Oestrogen Valerate Ethinyl Estradiol Premarin Seal JECM :
44 Need for Augmentation by Testosterone Suppression Type Subjects (%) ** Augmentation No Augmentation 0 Antiandrogen Cyproterone Acetate Finasteride Spironolactone Dutasteride GnRH Seal JECM :
45
46 Endocrine Society Guidelines 2017 JCEM 2017, 102(11):1 35
47 Standard preoperative treatment protocol at Charing Cross Hospital Gender Identity Clinic Oestrogen Valerate 2-10mg/day Decapeptyl 11.25mg/12wk or Transdermal Oestrogen Valerate Gel 1-4mg/day Patches (50-200mgx2/week) or Ethinyl oestradiol μg/d
48 Standard preoperative treatment protocol at Charing Cross Hospital Gender Identity Clinic Monitoring 8 weeks after starting a new dose of medication Dose increased every 3 months until target range achieved or maximum dose Level of Oestradiol is sub optimal on oral dosing change to topical preparations
49 Oestradiol (pmol/l) A Comparison Between oral and Topical Oestrogen 11.3% have suboptimal oestrogen level on oral oestrogen Oral
50 Post GRS Doses Doses reduce by half post operatively if on suppressive oestrogen Preop dose continued if on GnRH analogues
51 Contraindications History of Breast Cancer History of Prostate cancer Thromboembolism Active Recurrent Focal migraine Dubin-Johnston and Rotor syndromes
52 Relative Contraindications Obesity Smoking Ischaemic heart disease Single DVT Family history of breast cancer Family history of thromboembolism Migraine Sickle cell disease Gall stones
53 VTE Risk in Women Taking Oral Contraceptive Pill Pomp Am J Haematol
54 VTE by Weight Category in Combined Oral contraceptive users Farmer 2000 Br J Clin Pharmacol, 49, 580±590
55 Morbidity in 816 Transwomen Venous thrombosis/pe Postoperative After Trauma Without Cause Myocardial Infarction (6 fatal) Angina Pectoris Cerebrovascular Disease TIA Intracranial Haemorrhage Occlusion of Leg Artery Hypertension (>160/95mmHg) Prostatic Carcinoma Elevation of Prolactin (>1000mU//l) Elevation of Liver Enzymes Transient (<6 months) Persistent (>6 months) Hepatitis B Alcohol related Others Cholelithiasis (5 Preexistent) HIV Seroconversion (3 died of AIDS) No. Observed SIR (95% CI) [ ] 0.05 [ ] NA 1.71 [ ] NA 0.98 [ ] 0.91 [ ] [ ] [ ] [ ] NA Van Kesteren Clin Endo
56 Morbididty: Male to Female Thromboembolism x20 (14%) 60% in first year 0.4% annual incidence Hyperprolactinaemia x80 Gall Stones X5 MI rate half expected
57 Thromboembolism Risk By Oestrogen Type 6 * 5 Thromboemolism (%) Oestrogen Valerate Ethinyestradiol Premarin
58 Effect of Oestrogens on Coagulation factors in Transpeople CPA-only (open bars), td-e2+cpa (shaded bars), and oral-ee+cpa (solid bars), F M transsexuals with T esters (hatched bars). PT, Prothrombin; PS, protein S; PC, protein C. 1 Toorians AW, J Clin Endocrinol Metab 2003; 88(12):
59 Side effects of Hormone Treatment in Transwomen Type of oestrogen Adverse event Oestrogen Valerate N= 163 Ethinyl Estradiol N= 132 CEE N= 45 Total (of population) N=342 Depression Thromboembolism * 1.2 Flushing Hair Loss 2.5* Hyperprolactinaemia Hypertension Diabetes Abnormal Liver Function Seal JECM :
60 Other Therapies Anti androgens Cyproterone acetate Finasteride
61 Other Therapies Anti androgens Cyproterone acetate Finasteride Abnormal LFT Liver Tumours Depression Meningioma
62 Other Therapies Anti androgens Cyproterone acetate Finasteride Abnormal LFT Liver Tumours Depression Meningioma Oestrogen receptor agonists Spironolactone
63 Other Therapies Anti androgens Cyproterone acetate Finasteride Abnormal LFT Liver Tumours Depression Meningioma Oestrogen receptor agonists Spironolactone Abnormal U +E Abnormal LFT Hyperkallaemia
64 Other Therapies Anti androgens Cyproterone acetate Finasteride Abnormal LFT Liver Tumours Depression Meningioma Oestrogen receptor agonists Spironolactone Abnormal U +E Abnormal LFT Hyperkallaemia GnRH analogues
65 Other Therapies Anti androgens Cyproterone acetate Finasteride Abnormal LFT Liver Tumours Depression Meningioma Oestrogen receptor agonists Spironolactone Abnormal U +E Abnormal LFT Hyperkallaemia GnRH analogues (Menopausal symptoms)
66 Progesterone Not produced until ovulatory Menstruation Increases Body temperature Secretory endometrium Thick cervical mucus Low vaginal ph Pregnancy Inhibits uterine contraction Decrease in smooth muscle tone Alveolar growth in the breast Increased fluid in stroma
67 Action of Progesterone Not produced until ovulatory No role in pubertal breast development Induces 17β HSD to inactivate Oestradiol Inhibits oestrogen induced proliferation Natriuretic Decreases Mood
68 Gender Identity Clinic Charing Cross Hospital
69 Monitoring Preparation Dose Frequency Oestradiol Values Oestradiol Valerate: Progynova Climaval Or Oestradiol Hemihydrate: Zumenon Patches: Estradot Everol Topical Gel: Sandrena Implants Oestrogen Implant 1mg and 2mg tablets 50mcg 200mcg twice weekly 0.5mg to 1mg sachets mg Take all at same time Change patch/es twice a week Apply to anywhere on body except breasts 6-24monthly pmol/L As above Monitoring Method Bloods should be drawn 4-6 hours after taking tablets Blood 48 hours after patch application As above Bloods 4 6 hours after application and no gel on the arms. Trough value of pmol/l 5 months after implant then repeated monthly Maximum Dose 8mg daily 200mcg x2/week 5mg daily 150mg
70 Monitoring LFT s, Oestradiol Testosterone SHBG Prolactin. For timings see previous If dose changed bloods to taken 8 weeks after the change. Once stabilised bloods should be taken six monthly for two years then annually
71 Considerations with Age Treatment is Lifelong Breast Cancer risk Background male risk Over 40 (Consider topical therapy) Over 50 as recommended by national guidelines Mammography PSA screen DEXA Aortic Aneurysm
72
Information About Hormonal Treatment for Trans women
Information About Hormonal Treatment for Trans women Leighton J Seal PhD FRCP Consultant Endocrinologist, Gender Identity Clinic, (Charing Cross) West London Mental Health NHS Trust 12/12/2016 1 Introduction...
More informationTransgender Medicine beyond the guidelines.
Transgender Medicine beyond the guidelines. Rachel Hopkins, MD Assistant Professor of Medicine SUNY Upstate Medical University Division of Endocrinology and Metabolism Overview Definitions and history
More informationPrescribing Guidelines
Porterbrook Clinic Sheffield Gender Identity Clinic Michael Carlisle Centre 75 Osborne Road Sheffield S11 9BF Version V10 22-01-18 Tel: 0114 271 6671 Fax: 0114 271 8693 Email: Porterbrook@shsc.nhs.uk Website:
More informationGUIDELINES FOR THE USE OF FEMINISING HORMONE THERAPY IN GENDER DYSPHORIA. Information for Primary Care December 2015 (Review Date June 2016)
GUIDELINES FOR THE USE OF FEMINISING HORMONE THERAPY IN GENDER DYSPHORIA Information for Primary Care December 2015 (Review Date June 2016) Further information on this guideline can be obtained from: Claire
More informationNorth of Tyne and Gateshead Area Prescribing Committee GUIDELINES FOR THE USE OF FEMINISING HORMONE THERAPY IN GENDER DYSPHORIA
North of Tyne and Gateshead Area Prescribing Committee GUIDELINES FOR THE USE OF FEMINISING HORMONE THERAPY IN GENDER DYSPHORIA Information for Primary Care July 2014 (Minor update November 2014) (Review
More informationFeminising hormone treatment for trans women and non-binary people: Information for primary care professionals
1 Feminising hormone treatment for trans women and non-binary people: Information for primary care professionals Introduction The following information has been produced by the Nottingham Centre for Transgender
More informationInformation About Hormonal Treatment for Trans men
Information About Hormonal Treatment for Trans men Leighton J Seal PhD FRCP Consultant Endocrinologist, Gender Identity Clinic, (Charing Cross) West London Mental Health NHS Trust 12/12/2016 Introduction...
More informationNational Gender Identity Clinical Network for Scotland (NGICNS)
National Gender Identity Clinical Network for Scotland (NGICNS) Endocrine Management of Adult Transgender Patients Revised 7 th July 2016 (First published 11 August 2015) This guidance is based on the
More informationOestrogen, progestogens and assessing risks of hormones. Dr Naomi Achong BSc MBBS(Hons) FRACP Endocrinologist
Oestrogen, progestogens and assessing risks of hormones Dr Naomi Achong BSc MBBS(Hons) FRACP Endocrinologist My interest Minimal exposure during training Unmet need within endocrinology (private/public)
More informationWhat to Know a 21 st Century Approach to Transgender Medical Care
What to Know a 21 st Century Approach to Transgender Medical Care Joshua Safer, MD Transgender Medicine Research Group Center for Transgender Medicine and Surgery Patient / Mental Health Provider Gatekeeper
More informationSHARED CARE PRESCRIBING GUIDANCE FOR
SHARED CARE PRESCRIBING GUIDANCE FOR (People transitioning from a male to feminine gender identity ) Applicable to: GPs referring patients to the Charing Cross Gender Identity Clinic Date Approved: 14
More informationState of California, California Health and Human Services Agency, Department of Managed Health Care 2013:
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More information10/07/18. Conflict of interest statement
Care: principles, best practices in Europe and how reproductive/sexual health care providers might contribute Petra De Sutter University Hospital Gent Conflict of interest statement My department occasionally
More informationHormone Therapy Overview for the Behavioral Health Provider. Julie Thompson, PA Fenway Health
Hormone Therapy Overview for the Behavioral Health Provider Julie Thompson, PA Fenway Health Continuing Medical Education Disclosure Program Faculty: Julie Thompson, PA Current Position: Physician s Assistant,
More informationPatient education for transgender feminizing hormone therapy
Date name DOB Patient education for transgender feminizing hormone therapy o Some transsexual, transgender, and gender non-conforming people choose to take hormone therapy to treat gender dysphoria and
More informationEndocrinology and the Transgender Patient
Endocrinology and the Transgender Patient Matthew Leinung MD Professor of Medicine Albany Medical College This project is supported by the Health Resources and Services Administration (HRSA) of the U.S.
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationGuidelines for the Clinical Care of Persons with Gender Dysphoria
Guidelines for the Clinical Care of Persons with Gender Dysphoria Friday, May 27, 2016 2:15 5:00 PM 25 th Annual Scientific and Clinical Congress American Association of Clinical Endocrinologist Orlando,
More informationGuidelines for the Clinical Care of Persons with Gender Dysphoria
Guidelines for the Clinical Care of Persons with Gender Dysphoria Friday, May 27, 2016 2:15 5:00 PM 25 th Annual Scientific and Clinical Congress American Association of Clinical Endocrinologist Orlando,
More informationPharmacy Policy. Adult transgender hormonal therapy may be approved when all of the following criteria are met:
Pharmacy Policy Class: Transgender Hormonal Treatment for Adults Line of Business: Medi-Cal Effective date: February 15, 2017 Revision date: February 15, 2017 This policy has been developed through review
More informationTransgender Health Cases from the Transgender and Intersex Specialty Care Clinic
Transgender Health Cases from the Transgender and Intersex Specialty Care Clinic Caroline Davidge-Pitts, MD Todd B Nippoldt, MD Department of Endocrinology, Diabetes, Nutrition Mayo Clinic, Rochester 2017
More informationGender Health Center, Hormone Clinic th St #201 Sacramento, CA 95817
MTF Clinical Approach and Protocols Gender Health Center, Hormone Clinic Sacramento, CA Katherine Gardner, MD Revised 11/6/2015 Name and Pronouns: Preferred names and pronouns are used at all times when
More informationGender dysphoria an update for general physicians
Gender dysphoria an update for general physicians Simon Page Consultant Endocrinologist Regional RCP meeting Feb 2018 1 Terminology Transvestism Sexual interest in cross-dressing Disorder of Sexual Development
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationEndocrine Treatment of Gender-Dysphoric/ Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. Education Module June, 2017
Endocrine Treatment of Gender-Dysphoric/ Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline Education Module June, 2017 Introduction Wylie C. Hembree, MD Associate Attending Physician
More informationTestosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E
Testosterone Treatment: Myths Vs Reality Fadi Al-Khayer, M.D, F.A.C.E The Biological Functions of Testosterone in Men Testosterone is essential to the musculoskeletal and metabolic systems throughout a
More informationHEALTH: Presented by: Alsean R. Bryant, Pharm.D., AAHIVP AIDS Healthcare Foundation
HEALTH: Presented by: Alsean R. Bryant, Pharm.D., AAHIVP AIDS Healthcare Foundation 1 The presenter has no actual or potential conflict of interest in relation to this presentation program. 2 Pharmacists:
More informationHypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.
Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology
More informationTransgender Medicine: Essentials for the Primary Care Provider BENJAMIN J. BOH, DO, MS
Transgender Medicine: Essentials for the Primary Care Provider BENJAMIN J. BOH, DO, MS ASSISTANT PROFESSOR OF MEDICINE SECTION OF ENDOCRINOLOGY GEISEL SCHOOL OF MEDICINE AT DARTMOUTH Disclosure I will
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone Oral Buccal Nasal Description
More informationAndroderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
More informationSHARED CARE PRESCRIBING GUIDANCE FOR
SHARED CARE PRESCRIBING GUIDANCE FOR Treatment of Gender Dysphoria in Transmen (People transitioning from a female to masculine gender identity ) Applicable to: GPs referring patients to the Charing Cross
More informationGENDER NON-CONFORMING / TRANSGENDER YOUTH: ENDOCRINE CONSIDERATIONS DISCLOSURE: I have nothing to disclose WHY STUDY GENDER?
GENDER NON-CONFORMING / TRANSGENDER YOUTH: ENDOCRINE CONSIDERATIONS DISCLOSURE: I have nothing to disclose Stephen M. Rosenthal, M.D. Professor of Pediatrics University of California, San Francisco Stephen
More informationCorporate Medical Policy
Corporate Medical Policy Gender Confirmation Surgery and Hormone Therapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gender_confirmation_surgery_and_hormone_therapy 7/2011 5/2018
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone Oral Buccal Nasal
More information12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
More information8/17/2015. Objectives. Disclosures
NPANY Annual Conference Niagara Falls, NY October 2015 Laura Markwick, DNP, FNP C Associate Professor Wegmans School of Nursing St Joh Fisher College Objectives The learner will gain an understanding of
More informationPatient education for transgender masculinizing hormone therapy
Date name DOB Patient education for transgender masculinizing hormone therapy o Some transsexual, transgender, and gender non-conforming people choose to take hormone therapy to treat gender dysphoria
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone
More informationGUIDELINES ON MALE HYPOGONADISM
GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationGENDER NON-CONFORMING / TRANSGENDER YOUTH: ENDOCRINE CONSIDERATIONS DISCLOSURE: I have nothing to disclose WHY STUDY GENDER?
GENDER NON-CONFORMING / TRANSGENDER YOUTH: ENDOCRINE CONSIDERATIONS DISCLOSURE: I have nothing to disclose Stephen M. Rosenthal, M.D. Professor of Pediatrics University of California, San Francisco Stephen
More informationPharmacists' role in pharmacotherapy management of transgender patients
Pharmacists' role in pharmacotherapy management of transgender patients Ashley Floyd, Pharm.D. PGY1 Community Pharmacy Residency Program H-E-B Pharmacy The University of Texas at Austin 1 Objectives Recognize
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: June 24, 2016 Testosterone Oral Buccal Nasal Description
More informationProviding Primary Care for Gender-Diverse Clients. Seaway Valley Community Health Centre June 30 th, 2016 Jennifer Douek, Jordan Zaitzow
Providing Primary Care for Gender-Diverse Clients Seaway Valley Community Health Centre June 30 th, 2016 Jennifer Douek, Jordan Zaitzow Introductions Jennifer Douek, MD Jordan Zaitzow, MSW Faculty / Presenter
More informationGUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde
GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
More informationTopics. Periods Menopause & HRT Contraception Vulva problems
Girls stuff Topics Periods Menopause & HRT Contraception Vulva problems Menorrhagia Excessive menstrual loss occurring with regular or irregular cycles Ovulatory Anovulatory Usual blood loss 30-40ml per
More informationDisclosures. Endocrine Care of the Transgender Patient. Objectives. Start where you are. Use what you have. Do what you can. Vocabulary.
Disclosures Endocrine Care of the Transgender Patient Kathryn Tierney, MSN, APRN, FNP-BC Medical Director, Middlesex Hospital Transgender Medicine Program Middlesex Multispecialty Group Division of Endocrinology
More informationFLASH CARDS. Kalat s Book Chapter 11 Alphabetical
FLASH CARDS www.biologicalpsych.com Kalat s Book Chapter 11 Alphabetical alpha-fetoprotein alpha-fetoprotein Alpha-Fetal Protein (AFP) or alpha-1- fetoprotein. During a prenatal sensitive period, estradiol
More informationFertility Issues for Transgender Persons. Timothy Cavanaugh, MD Fenway Health
Fertility Issues for Transgender Persons Timothy Cavanaugh, MD Fenway Health Transgender refers to a person who is born with the genetic traits of one gender but has the internalized identity of another
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Limited text update March 2017) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationBy Dr Rukhsana Hussain 5 th April 2016
By Dr Rukhsana Hussain 5 th April 2016 1. Is it indicated? Vasomotor symptoms (flushes/sweats) Vaginal atrophy Cycle control (In perimenopause consider low dose COCP (age
More informationArti Barnes MD MPH Tuesday AM series ENCOMPASSING THE MARGINALIZED: CARE FOR THE TRANSGENDER COMMUNITY
Arti Barnes MD MPH Tuesday AM series 9-29-2015 ENCOMPASSING THE MARGINALIZED: CARE FOR THE TRANSGENDER COMMUNITY Disclosures None Objectives Increase awareness of HIV and STD epidemiology among Transgenders
More informationProf. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany
Induction of fertility in hypogonadal men Prof. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany Induction of fertility in hypogonadal men Prof.
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: December 8, 2017 Testosterone
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by
More informationEvaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients
Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008
More information22/09/2014. Menopause Management. Menopause. Menopause symptoms
Menopause Management Dr Sonia Davison Jean Hailes for Women s Health Menopause Time of last menstrual period - average age 51 Premature Menopause: occurs before age 40 Perimenopause (menopause transition):
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acquired hypogonadism, prevalence of, 165 167 primary, 165 secondary, 167 Adipose tissue, as an organ, 240 241 Adrenal hyperplasia, congenital,
More informationGENder Education and Care Interdisciplinary Support (GENECIS) Feminizing Medications for Patients with Gender Dysphoria
GENder Education and Care Interdisciplinary Support (GENECIS) Feminizing Medications for Patients with Gender Dysphoria Patient Information and Informed Consent and Assent for Minors Before using medications
More informationMale Hypogonadism. Types and causes of hypogonadism. What is male hypogonadism? Symptoms. Testosterone production. Patient Information.
Patient Information English 31 Male Hypogonadism The underlined terms are listed in the glossary. What is male hypogonadism? Male hypogonadism means the testicles do not produce enough of the male sex
More informationDISCLOSURES LEARNING OBJECTIVES. 21st Century Strategies: Transgender Hormone Care. Patient/PCP. Medical model
21st Century Strategies: Transgender Hormone Care DISCLOSURES Joshua Safer, MD Center for Transgender Medicine and Surgery No conflicts of interest Just about the entire talk is "off label" LEARNING OBJECTIVES
More informationHormonal Control of Human Reproduction
Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with
More informationLate onset hypogonadism
Late onset hypogonadism Farrukh Javid Male Menopause Clinical AND biochemical syndrome Testosterone levels decline by 0.4-3% per year after the age of 30, as opposed to the more rapid decline that occurs
More informationClass 15: Sex (Part 2)
Notes By: Snehapriya October 17, 2017 HUMAN SEXUAL BEHAVIOR Class 15: Sex (Part 2) - What makes sexual behaviors different between adult males and females? - Hypothesis: Activational effect of hormones
More informationCh 20: Reproduction. Keypoints: Human Chromosomes Gametogenesis Fertilization Early development Parturition
Ch 20: Reproduction Keypoints: Human Chromosomes Gametogenesis Fertilization Early development Parturition SLOs Contrast mitosis/meiosis, haploid/diploid, autosomes/sex chromosomes. Outline the hormonal
More informationWestern Locality Shared care information ~ Gonadorelin Analogues (Gnrh)
Western Locality Shared care information ~ Gonadorelin Analogues (Gnrh) Specialist: Please complete the Shared Care letter sending a request to GP (see bottom of the page) April 2013 GP: Please indicate
More information2-Hypertrichosis:- Hypertrichosis is the
Hirsutism And Virilization Hirsutism:- Is the development of androgen-dependent dependent terminal body hair in a woman in places in which terminal hair is normally not found, terminal body hairs are the
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone
More informationReproductive System. Testes. Accessory reproductive organs. gametogenesis hormones. Reproductive tract & Glands
Reproductive System Testes gametogenesis hormones Accessory reproductive organs Reproductive tract & Glands transport gametes provide nourishment for gametes Hormonal regulation in men Hypothalamus - puberty
More informationMODULE 1 F E M I N I Z I N G
MODULE 1 F E M I N I Z I N G MODULE 1 MEDICAL TRANSITION - FEMINIZING Objectives: Describe the basic science underpinning feminizing gender hormonal transition List the pharmacologic options including
More informationPolycystic Ovarian Syndrome (PCOS) LOGO
Polycystic Ovarian Syndrome (PCOS) Ma qianhong Ob/Gyn Department LOGO Contents Epidemiology and Definition Pathophysiology, Endocrinological Features Diagnostic Criteria Treatment Prognosis Introduction
More informationReproductive System (Hormone Function) Physiology Department Medical School, University of Sumatera Utara
Reproductive System (Hormone Function) Physiology Department Medical School, University of Sumatera Utara 1 Endocrine Control: Three Levels of Integration Hormones of the hypothalamic-anterior pituitary
More informationHyperandrogenism and polycystic ovary syndrome are clear casual factors (trends) which result in hirsuitism and acne.
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Indication: Treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism,
More informationBIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE
Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation
More informationISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN
International Society for Sexual Medicine - www.issm.info ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN Version: September 2015 What is testosterone deficiency? Testosterone deficiency
More informationReproductive physiology. About this Chapter. Case introduction. The brain directs reproduction 2010/6/29. The Male Reproductive System
Section Ⅻ Reproductive physiology Ming-jie Wang E-Mail: mjwang@shmu.edu.cn About this Chapter The reproductive organs and how they work the major endocrine functions of sexual glands actions of sex hormones
More informationMULTIPLE CHOICE. Choose the one alternative that best completes the statement or answers the question.
MULTIPLE CHOICE. Choose the one alternative that best completes the statement or answers the question. 1) Which of the following hormones controls the release of anterior pituitary gonadotropins? A) LH
More information06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence:
Menopause Dr Sonia Davison MBBS FRACP PhD Endocrinologist and Clinical Fellow, Jean Hailes for Women s Health Women s Health Research Program, Monash University = the last natural menstrual period depletion
More informationTHE SAFETY CHECK LIST BEFORE STARTING HT
THE SAFETY CHECK LIST BEFORE STARTING HT This safety checklist was designed by the Endocrine Society in 2015 to minimize the chance of giving hormone therapy to women who may be negatively affected by
More informationSexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist
Sexual dysfunction of chronic kidney disease Razieh salehian.md psychiatrist Disturbances in sexual function are a common feature of chronic renal failure. Sexual dysfunction is inversely associated with
More informationDianette (cyproterone acetate 2mg/ethinylestradiol 35 mcg): Strengthening of warnings, new contraindications, and updated indication
Dianette (cyproterone acetate 2mg/ethinylestradiol 35 mcg): Strengthening of warnings, new contraindications, and updated indication Dear Healthcare Professional, In agreement with the European Medicines
More informationAndrogen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital
Androgen deficiency Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Outline Pathological androgen deficiency - Background, causes, interpretation - Indications for treatment Androgen
More informationANDROGEN DEFICIENCY/MALE HYPOGONADISM
ANDROGEN DEFICIENCY/MALE HYPOGONADISM 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone (androgen deficiency)
More informationHORMONES & REPRODUCTION OUTLINE
1 HORMONES & REPRODUCTION Dr. Steinmetz OUTLINE 2 The Endocrine System Sexual Reproduction Hormonal Role in Sexual Differentiation Gender Differences and Gender Identity Characterizing Complex Behaviors
More informationAssisted Reproductive Technology (ART) / Infertility / Synarel (nafarelin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.03 Subject: Synarel Page: 1 of 5 Last Review Date: September 15, 2016 Synarel Description Assisted
More informationAmenorrhoea: polycystic ovary syndrome
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationwww.iffs-reproduction.org @IntFertilitySoc Int@FedFertilitySoc Conflict of interest none Outline Causes of ovulatory dysfunction Assessment of women with ovulatory dysfunction Management First line Second
More informationGONADAL FUNCTION: An Overview
GONADAL FUNCTION: An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences Clinical Biochemistry BMLS III & BDS IV VJ Temple 1 What are the Steroid hormones?
More informationA Practitioner s Toolkit for the Management of the Menopause
Medicine, Nursing and Health Sciences A Practitioner s Toolkit for the Management of the Menopause Developed by the Women s Health Research Program School of Public Health and Preventive Medicine Monash
More informationBiology of Reproduction-Biol 326
Biology of Reproduction-Biol 326 READ ALL INSTRUCTIONS CAREFULLY. ANSWER ALL THE QUESTIONS ON THE ANSWER SHEET. THE ANSWER ON THE ANSWER SHEET IS YOUR OFFICIAL ANSWER REGARDLESS OF WHAT YOU MARK ON THE
More informationDidactic Series. Hypogonadism and HIV. Daniel Lee, MD UCSD Medical Center, Owen Clinic July 28, 2016
Didactic Series Hypogonadism and HIV Daniel Lee, MD UCSD Medical Center, Owen Clinic July 28, 2016 This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department
More informationLaboratory Investigation of Male Gonadal Function. Dr N Oosthuizen Dept of Chemical Pathology UP 2010
Laboratory Investigation of Male Gonadal Function Dr N Oosthuizen Dept of Chemical Pathology UP 2010 1 Figure 1. Hypothalamic-pituitary pituitary-testicular testicular axis 2 Testosterone (T) measurement
More informationFemale Reproductive Endocrinology
Female Reproductive Endocrinology Dr. Channa Jayasena PhD MRCP FRCPath Clinical Senior Lecturer & Consultant Endocrinologist Department of Gynaecology, Hammersmith Hospital Anovulation is a common cause
More informationTRANSPARENCY COMMITTEE OPINION. 19 July 2006
TRANSPARENCY COMMITTEE The legally binding text is the original French version OPINION 19 July 2006 ANDROCUR 100 mg, scored tablet 3 blister packs 20 tablets : 340 417-5 Applicant: Schering SA cyproterone
More informationPremature Menopause : Diagnosis and Management
Guideline Number 3 : August 2010 Premature Menopause : Diagnosis and Management Introduction : Premature menopause is a serious condition that affects young women and remains an enigma. The challenges
More informationREPRODUCTIVE ENDOCRINOLOGY
Overview REPRODUCTIVE ENDOCRINOLOGY Specialist Portfolio Seminar 23 rd June 2014 Katie Jones Sandwell and West Birmingham Hospitals NHS Trust Hypothalamic pituitary gonadal axis Females Males Overview
More informationMULTIPLE CHOICE: match the term(s) or description with the appropriate letter of the structure.
Chapter 27 Exam Due NLT Thursday, July 31, 2015 Name MULTIPLE CHOICE: match the term(s) or description with the appropriate letter of the structure. Figure 27.1 Using Figure 27.1, match the following:
More informationCare for Transgender Patient: Providing Competent and Compassionate Care During a Time of Transition
Care for Transgender Patient: Providing Competent and Compassionate Care During a Time of Transition Jessica Francis, MD Assistant Professor Department of Obstetrics and Gynecology Froedtert and the Medical
More informationINFORMED CONSENT FOR FEMINIZING HORMONE THERAPY
INFORMED CONSENT FOR FEMINIZING HORMONE THERAPY The use of hormone therapy for gender transition/affirmation is based on many years of experience treating trans persons. Research on hormone therapy is
More information